Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16799899 | 1.00 | ACACB (0.40) | ACACBPDE5AHPGDALOX5EPHX2 | |
| SCHEMBL20810563 | 0.90 | NPSR1 (0.39) | ACACBPDE5AHPGDALOX5EPHX2 | |
| SCHEMBL17977253 | 0.90 | ACACB (0.41) | ACACBPDE5AALOX5EPHX2 | |
| SCHEMBL16799810 | 0.86 | ALDH1A1 (0.38) | ACACBPDE5AHPGDALOX5EPHX2 | |
| SCHEMBL16799811 | 0.86 | ALDH1A1 (0.38) | ACACBPDE5AHPGDALOX5EPHX2 | |
| SCHEMBL20810488 | 0.85 | ACACB (0.42) | ACACBPDE5AHPGDNPSR1NPC1 | |
| SCHEMBL16802548 | 0.85 | ACACB (0.42) | ACACBPDE5AHPGDNPSR1NPC1 | |
| SCHEMBL16799996 | 0.85 | NPSR1 (0.39) | ACACBPDE5AHPGDALOX5EPHX2 | |
| SCHEMBL16800055 | 0.85 | NPSR1 (0.39) | ACACBPDE5AHPGDALOX5EPHX2 | |
| SCHEMBL16799995 | 0.85 | NPSR1 (0.39) | ACACBPDE5AHPGDALOX5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077369-B1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9908843-B2 | Benzamide derivatives useful in the treatment of muscular disorders and pain and for controlling spasticity and tremors | CANBEX THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| EP-3256112-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | Canbex Therapeutics Limited (GB) | 2017-12-20 | — | — | EP | disclosed |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2016-10-20 | — | — | US | disclosed |
| EP-3077369-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERSAND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | Canbex Therapeutics Limited (GB) | 2016-10-12 | — | — | EP | disclosed |
| WO-2016128771-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| WO-2015082938-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERSAND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | CANBEX THERAPEUTICS LIMITED (GB) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | HCN4, KCNJ4, KCNQ4 | ACACB 3843/4885PDE5A 1773/4885HPGD 2385/4885 |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | MUSK, MYLK2, CBR3 | ACACB 1863/4885PDE5A 2504/4885HPGD 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.